Welcome to our dedicated page for Harvard Bioscience news (Ticker: HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Bioscience stock.
Harvard Bioscience Inc. (NASDAQ: HBIO) is a global developer, manufacturer, and marketer of specialized products and scientific instruments that advance life science research. With a focus on enabling fundamental research, discovery, and pre-clinical testing for drug development, Harvard Bioscience serves a diverse range of customers, including pharmaceutical and biotechnology companies, universities, and government laboratories worldwide.
The company’s comprehensive product portfolio includes brands such as Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab. These products are used in various applications, from basic research to complex pre-clinical studies, and are distributed in over 100 countries through direct sales, catalogs, websites, and partnerships with renowned distributors like GE Healthcare, Thermo Fisher Scientific Inc., and VWR.
Harvard Bioscience operates manufacturing and sales facilities in the United States, the United Kingdom, Germany, and Spain, with additional sales operations in France and Canada. The company’s primary revenue stream comes from the United States, but it maintains a significant presence in North America, Europe, and China.
Recently, Harvard Bioscience has introduced several innovative solutions to enhance the efficiency and throughput of its customers’ research activities. These include the DSI™ Ponemah™ Data Management Platform with integrated solutions like SoHo™ implantable telemetry for small animal models and the VivaMARS™ high-capacity behavior monitoring system. These advancements support more natural research environments and longitudinal studies, reduce operating costs, and open opportunities for emerging machine learning algorithms to analyze large data sets efficiently.
Another significant innovation is the MCS™ Mesh MEA™ Organoid Platform, which allows researchers to capture precise electrophysiology measurements from within living organoids in real time. This platform is designed for applications in safety pharmacology and toxicology and supports the growing use of organoids in research and discovery.
Harvard Bioscience continues to focus on organizational efficiencies and aligning its global operating structure with strategic growth priorities. The recent labor force reduction aims to improve operating cost structure and support ongoing investments in growth, with expected annual run rate savings of approximately $4 million starting in the second quarter of 2024.
For more information about Harvard Bioscience and its innovative products, please visit https://www.harvardbioscience.com.
Harvard Bioscience (Nasdaq: HBIO) is set to announce its Q2 financial results for the period ending June 30, 2022, before the market opens on August 4, 2022. A conference call will follow at 8:00 AM ET for discussions on the financial results.
Participants interested in joining the call can register here.
Harvard Bioscience reported a 7% year-over-year revenue increase for Q1 2022, reaching $28.8 million, despite COVID-19 lockdowns in China affecting operations. Strong North American sales and demand for pre-clinical and cellular/molecular products were key drivers. However, the company faced an operating loss of $6.7 million, influenced by higher material costs and a $5 million legal accrual. Adjusted operating income fell to $2.4 million, with adjusted margins down to 8.2%. Looking ahead, the company expects annual revenue growth of 8% to 13%, alongside improving gross margins.
Harvard Bioscience (Nasdaq: HBIO) has launched SmartStudy™, a new feature for its Buxco® Inhalation System, enhancing precision and cost-efficiency in small animal research. This technology allows researchers to stop the delivery of test articles to individual subjects once the desired dosage is achieved, minimizing error and optimizing resource use. Demonstrations of SmartStudy™ occurred at the Society of Toxicology meeting and will continue at the American Thoracic Society conference. The innovation aims to significantly improve inhalation study methodologies.
Harvard Bioscience, Inc. (Nasdaq: HBIO) is set to announce its financial results for Q1 2022 on May 4, 2022, before market opening. A conference call to discuss these results will take place at 8:00 a.m. ET. Interested parties can join the call by calling toll-free 1 (877) 303-7611 or international 1 (970) 315-0445, using conference ID #6757353. The call will also be available via webcast on the company’s investor relations website.
Harvard Bioscience develops technologies for research and drug development, serving a wide range of clients globally.
Harvard Bioscience reported a 7% revenue increase year-over-year in Q4 2021, totaling $33.1 million, despite global supply chain challenges. Gross margin improved to 59%, fueled by a stronger product mix. Pre-clinical product revenue rose by 18% for the full year, while CMT products grew by 9% in Q4. However, operating income dipped to $1.7 million due to rising material and labor costs. The company anticipates 10-13% revenue growth for 2022, with plans for increased investment in sales and R&D.
Harvard Bioscience (Nasdaq: HBIO) is set to announce its fourth-quarter financial results for the period ending December 31, 2021, on March 8, 2022, prior to market opening. The company will hold a conference call at 8:00 a.m. Eastern Time to discuss these results. Investors can participate by dialing the provided numbers or via the live webcast accessible through their website. Harvard Bioscience specializes in developing technologies for fundamental research and drug development, serving various sectors from academia to pharmaceuticals.
Harvard Bioscience reported a 23% year-over-year revenue growth for Q3 2021, reaching $29.7 million, with pre-clinical product revenue up 28% and Cellular and Molecular Technologies (CMT) product revenue up 19%. Operating income showed a slight increase from $0.2 million to $0.5 million. Despite ongoing global supply chain disruptions impacting costs, adjusted operating margin remained solid at 13.3%. The company expects revenue growth of 15% to 17% for the year, up from previous estimates of 12% to 15%.
Harvard Bioscience (Nasdaq: HBIO) will announce its third-quarter financial results on November 3, 2021, prior to market opening. The announcement will be followed by a conference call at 8:00 a.m. Eastern Time to discuss the results. Interested parties can join the call by dialing 1 (877) 303-7611 (toll-free) or 1 (970) 315-0445 (international), using conference ID # 8391005. Additionally, a live webcast will be available on the company's website, where the earnings release and presentation will also be accessible.
Harvard Bioscience, Inc. (Nasdaq: HBIO) reported a 25% year-over-year revenue growth for Q2 2021, reaching $29.2 million, driven by strong demand in pre-clinical and Cellular and Molecular (CMT) products, which grew by 20% and 22%, respectively. Despite higher global supply chain costs affecting operating margins, adjusted operating margins remained robust at 14.6%. Looking ahead, the company anticipates a 12% to 15% revenue growth for the fiscal year. Operating income was impacted, showing a loss per share of $(0.01), with adjusted diluted EPS at $0.06.
Harvard Bioscience (Nasdaq: HBIO) will release its financial results for Q2 2021 on August 5, 2021, prior to market opening. The announcement will be followed by a conference call at 8:00 a.m. ET, accessible via toll-free number 1 (877) 303-7611 or international number 1 (970) 315-0445, with conference ID # 6293853. The call will also be webcast through the Harvard Bioscience website. The results and accompanying slide presentation will be available on the Investor Relations section of their site.
FAQ
What is the current stock price of Harvard Bioscience (HBIO)?
What is the market cap of Harvard Bioscience (HBIO)?
What does Harvard Bioscience Inc. specialize in?
What are some of the key product brands of Harvard Bioscience?
In which countries does Harvard Bioscience operate?
Who are the primary customers of Harvard Bioscience's products?
How does Harvard Bioscience distribute its products?
What recent innovations has Harvard Bioscience introduced?
What is the focus of the MCS™ Mesh MEA™ Organoid Platform?
What are the benefits of the DSI™ Ponemah™ Data Management Platform?
What strategic actions has Harvard Bioscience taken recently?
Where can I find more information about Harvard Bioscience?
